Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V.

Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Erratum in: Blood. 2019 Feb 14;133(7):768.

PMID:
29907599
2.

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

Nakamura K, Kassem S, Cleynen A, Chrétien ML, Guillerey C, Putz EM, Bald T, Förster I, Vuckovic S, Hill GR, Masters SL, Chesi M, Bergsagel PL, Avet-Loiseau H, Martinet L, Smyth MJ.

Cancer Cell. 2018 Apr 9;33(4):634-648.e5. doi: 10.1016/j.ccell.2018.02.007.

3.

NK Cell-Specific CDK8 Deletion Enhances Antitumor Responses.

Witalisz-Siepracka A, Gotthardt D, Prchal-Murphy M, Didara Z, Menzl I, Prinz D, Edlinger L, Putz EM, Sexl V.

Cancer Immunol Res. 2018 Apr;6(4):458-466. doi: 10.1158/2326-6066.CIR-17-0183. Epub 2018 Jan 31.

4.

Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis.

Mittal D, Vijayan D, Putz EM, Aguilera AR, Markey KA, Straube J, Kazakoff S, Nutt SL, Takeda K, Hill GR, Waddell N, Smyth MJ.

Cancer Immunol Res. 2017 Dec;5(12):1098-1108. doi: 10.1158/2326-6066.CIR-17-0341. Epub 2017 Oct 25.

5.

NK cell heparanase controls tumor invasion and immune surveillance.

Putz EM, Mayfosh AJ, Kos K, Barkauskas DS, Nakamura K, Town L, Goodall KJ, Yee DY, Poon IK, Baschuk N, Souza-Fonseca-Guimaraes F, Hulett MD, Smyth MJ.

J Clin Invest. 2017 Jun 30;127(7):2777-2788. doi: 10.1172/JCI92958. Epub 2017 Jun 5.

6.

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.

Putz EM, Guillerey C, Kos K, Stannard K, Miles K, Delconte RB, Takeda K, Nicholson SE, Huntington ND, Smyth MJ.

Oncoimmunology. 2017 Feb 7;6(2):e1267892. doi: 10.1080/2162402X.2016.1267892. eCollection 2017.

7.

Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity.

Putz EM, Majoros A, Gotthardt D, Prchal-Murphy M, Zebedin-Brandl EM, Fux DA, Schlattl A, Schreiber RD, Carotta S, Müller M, Gerner C, Decker T, Sexl V.

Oncoimmunology. 2016 May 19;5(9):e1186314. eCollection 2016.

8.

Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia.

Klose R, Krzywinska E, Castells M, Gotthardt D, Putz EM, Kantari-Mimoun C, Chikdene N, Meinecke AK, Schrödter K, Helfrich I, Fandrey J, Sexl V, Stockmann C.

Nat Commun. 2016 Aug 19;7:12528. doi: 10.1038/ncomms12528.

9.

CIS is a potent checkpoint in NK cell-mediated tumor immunity.

Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, Stannard K, Zhang JG, Teh C, Firth M, Ushiki T, Andoniou CE, Degli-Esposti MA, Sharp PP, Sanvitale CE, Infusini G, Liau NP, Linossi EM, Burns CJ, Carotta S, Gray DH, Seillet C, Hutchinson DS, Belz GT, Webb AI, Alexander WS, Li SS, Bullock AN, Babon JJ, Smyth MJ, Nicholson SE, Huntington ND.

Nat Immunol. 2016 Jul;17(7):816-24. doi: 10.1038/ni.3470. Epub 2016 May 23.

PMID:
27213690
10.

STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion.

Gotthardt D, Putz EM, Grundschober E, Prchal-Murphy M, Straka E, Kudweis P, Heller G, Bago-Horvath Z, Witalisz-Siepracka A, Cumaraswamy AA, Gunning PT, Strobl B, Müller M, Moriggl R, Stockmann C, Sexl V.

Cancer Discov. 2016 Apr;6(4):414-29. doi: 10.1158/2159-8290.CD-15-0732. Epub 2016 Feb 12.

11.

Bench to bedside: NK cells and control of metastasis.

Krasnova Y, Putz EM, Smyth MJ, Souza-Fonseca-Guimaraes F.

Clin Immunol. 2017 Apr;177:50-59. doi: 10.1016/j.clim.2015.10.001. Epub 2015 Oct 23. Review.

PMID:
26476139
12.

In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.

Prchal-Murphy M, Witalisz-Siepracka A, Bednarik KT, Putz EM, Gotthardt D, Meissl K, Sexl V, Müller M, Strobl B.

Oncoimmunology. 2015 May 26;4(11):e1047579. eCollection 2015 Nov.

13.

Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice.

Pathria P, Gotthardt D, Prchal-Murphy M, Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J, Musteanu M, Hoffmann T, Filipits M, Berger W, Poli V, Kenner L, Bilban M, Casanova E, Müller M, Strobl B, Bayer E, Mohr T, Sexl V, Eferl R.

Oncoimmunology. 2015 Jan 22;4(4):e998529. eCollection 2015 Apr.

14.

STAT1-S727 - the license to kill.

Putz EM, Gotthardt D, Sexl V.

Oncoimmunology. 2014 Dec 13;3(9):e955441. eCollection 2014 Oct.

15.

NK cell development in bone marrow and liver: site matters.

Gotthardt D, Prchal-Murphy M, Seillet C, Glasner A, Mandelboim O, Carotta S, Sexl V, Putz EM.

Genes Immun. 2014 Dec;15(8):584-7. doi: 10.1038/gene.2014.55. Epub 2014 Oct 16.

PMID:
25319498
16.

Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance.

Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, Müller M, Sexl V.

Blood. 2014 Oct 9;124(15):2370-9. doi: 10.1182/blood-2014-03-564450. Epub 2014 Sep 2.

17.

CD52 is a molecular target in advanced systemic mastocytosis.

Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, Cerny-Reiterer S, Gleixner KV, Walz C, Hoetzenecker K, Müllauer L, Reiter A, Sotlar K, Sexl V, Valent P, Mayerhofer M.

FASEB J. 2014 Aug;28(8):3540-51. doi: 10.1096/fj.14-250894. Epub 2014 Apr 23.

PMID:
24760752
18.

Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance.

Putz EM, Hoelzl MA, Baeck J, Bago-Horvath Z, Schuster C, Reichholf B, Kern D, Aberger F, Sexl V, Hoelbl-Kovacic A.

Cancers (Basel). 2014 Jan 27;6(1):193-210. doi: 10.3390/cancers6010193.

19.

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.

Berger A, Hoelbl-Kovacic A, Bourgeais J, Hoefling L, Warsch W, Grundschober E, Uras IZ, Menzl I, Putz EM, Hoermann G, Schuster C, Fajmann S, Leitner E, Kubicek S, Moriggl R, Gouilleux F, Sexl V.

Leukemia. 2014 Mar;28(3):629-41. doi: 10.1038/leu.2013.351. Epub 2013 Nov 22.

20.

CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance.

Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, Straka E, Rigler D, Wallner B, Jamieson AM, Pickl WF, Zebedin-Brandl EM, Müller M, Decker T, Sexl V.

Cell Rep. 2013 Aug 15;4(3):437-44. doi: 10.1016/j.celrep.2013.07.012. Epub 2013 Aug 8.

21.

The tyrosine kinase Btk regulates the macrophage response to Listeria monocytogenes infection.

Köprülü AD, Kastner R, Wienerroither S, Lassnig C, Putz EM, Majer O, Reutterer B, Sexl V, Kuchler K, Müller M, Decker T, Ellmeier W.

PLoS One. 2013;8(3):e60476. doi: 10.1371/journal.pone.0060476. Epub 2013 Mar 27.

22.

Targeting PI3Kδ: One man's meat is another man's poison.

Prchal-Murphy M, Putz EM, Freissmuth M, Sexl V, Zebedin-Brandl E.

Oncoimmunology. 2013 Jan 1;2(1):e22272.

23.

Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance.

Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Müller M, Sexl V, Stoiber D.

Oncoimmunology. 2012 Oct 1;1(7):1027-1037.

24.

Bcl-2: Live and let die.

Putz EM, Schuster C, Sexl V.

Oncoimmunology. 2012 Aug 1;1(5):749-750.

25.

PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes.

Putz EM, Prchal-Murphy M, Simma OA, Forster F, Koenig X, Stockinger H, Piekorz RP, Freissmuth M, Müller M, Sexl V, Zebedin-Brandl E.

PLoS One. 2012;7(7):e40852. doi: 10.1371/journal.pone.0040852. Epub 2012 Jul 13.

26.

The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas.

Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O, Moritz N, Hoelbl A, Kovacic B, Freissmuth M, Müller M, Villunger A, Müllauer L, Schmatz AI, Streubel B, Porpaczy E, Jäger U, Stoiber D, Sexl V.

Blood. 2011 Oct 27;118(17):4635-45. doi: 10.1182/blood-2010-10-313098. Epub 2011 Aug 30.

PMID:
21878673
27.

In vivo long-term kinetics of radiolabeled n,n-dimethyltryptamine and tryptamine.

Vitale AA, Pomilio AB, Cañellas CO, Vitale MG, Putz EM, Ciprian-Ollivier J.

J Nucl Med. 2011 Jun;52(6):970-7. doi: 10.2967/jnumed.110.083246.

28.

Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.

Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, Chang-Rodriguez S, Lingnau K, Weisz E, Putz EM, Pickl WF, Felzmann T, Müller M, Decker T, Sexl V, Stoiber D.

Cancer Res. 2009 Jan 1;69(1):203-11. doi: 10.1158/0008-5472.CAN-08-1705.

29.

Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.

Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, Eckelhart E, Stoiber D, Weisz E, Schmid JA, Pickl WF, Baumgartner C, Valent P, Piekorz RP, Freissmuth M, Sexl V.

Blood. 2008 Dec 1;112(12):4655-64. doi: 10.1182/blood-2008-02-139105. Epub 2008 Aug 6.

PMID:
18684865
30.

Comparison of three different experimental methods for the assessment of peripheral compartment pharmacokinetics in humans.

Müller M, Brunner M, Schmid R, Putz EM, Schmiedberger A, Wallner I, Eichler HG.

Life Sci. 1998;62(15):PL227-34.

PMID:
9566779

Supplemental Content

Support Center